Announced Date: 2024-01-02 (January 2, 2024)
Asset Name: YL211 (RG6648)
Licensor: MediLink (MediLink Therapeutics, China)
Licensee (Buyer): Roche
.
Asset Modality: ADC (antibody drug conjugate)
Asset Target: c-Met (c-Mesenchymal epithelial transition factor)
Potential Indication: Solid tumors
Current Stage: IND stage
.
Scope of Authority:
MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink’s ADC asset, YL211.
MediLink will work together with Roche’s R&D unit China Innovation Center of Roche (CICoR) to initiate the Phase I clinical trial of YL211 and Roche will then take over the further development and commercialization globally.
.
Payment Detail:
Upfront and near-term milestone payments of $50 million,
Total payments up to $1 billion.
Tiered royalties on net sales.
.
Link:
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation ADC in Oncology
